“In some diseases, cells lose their ability to differentiate, and reproduce more rapidly. Being able to redirect cells back to their usual life cycle could alleviate the processes behind the disease,” said Aditi Kanhere, PhD.
Guselkumab, a biologic therapy that is part of a new class of agents targeting interleukin (IL)-23 without blocking IL-12, was approved in Nov. 2017 by Health Canada for the treatment of moderate to severe plaque psoriasis in adults.
The new therapy is more precisely targeted than some earlier biologics, Dr. Melinda Gooderham said during an interview with DERM.city.She was a researcher involved in clinical tr...
“After a series of tests carried out by Dr. Satveer Mahil at St. John’s Institute of Dermatology [at King’s College, London], we determined that the lack of IL-36 activation had not had an adverse effect on their health which suggests it would be safe to block this molecule in patients with psoriasis,” said Dr. Capon.
Canadian investigators have determined that apremilast—an oral phosphodiesterase 4 inhibitor—can be safely and effectively combined with at least one form of photosystemic, and/or biologic therapy in the treatment of patients with chronic plaque psoriasis.